Q1 earnings recap with Endpoints News
After a deal-heavy first quarter, earnings season is in full swing. We’re breaking down the news and trends from Big Pharma’s first-quarter calls on a special premium subscriber-exclusive episode …
Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research
Seaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. With a team largely made up of Karuna



